Medtronic Jewel PCD
This article was originally published in The Gray Sheet
Executive SummaryFirm launches two models of its Jewel PCD implantable defibrillators outside the U.S. The Model 7219D provides "full-feature tiered therapy," and the Model 7202D "offers basic defibrillation capabilities," Medtronic says. Because of their small size, the devices can be implanted near the shoulder rather than the abdominal area, which "significantly simplifies implantation," according to the firm. The devices have been undergoing clinical testing in Europe and Canada since March. U.S. clinical studies were initiated in September ("The Gray Sheet" Sept. 27, I&W-6)
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.